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Abstract
Background: Mammary carcinomas have been associated with a high-fat diet, and the rate of breast cancer in
overweight post-menopausal women is up to 50% higher than in their normal-weight counterparts.
Epidemiological studies suggest that prolactin (PRL) plays a role in the progression of breast cancer. The current
study examined breast cancer as a metabolic disease in the context of altered fatty acid catabolism by examining
the effect of PRL on carnitine palmitoyl transferase 1 (CPT1), an enzyme that shuttles long-chain fatty acids into the
mitochondrial matrix for b-oxidation. The effect of PRL on the adenosine 5’-monophosphate-activated protein
kinase (AMPK) energy sensing pathway was also investigated.
Methods: MCF-7 and MDA-MB-231 breast cancer cells and 184B5 normal breast epithelial cells treated with
100 ng/ml of PRL for 24 hr were used as in vitro models. Real-time PCR was employed to quantify changes in
mRNA levels and Western blotting was carried out to evaluate changes at the protein level. A non-radioactive
CPT1 enzyme activity assay was established and siRNA transfections were performed to transiently knock down
specific targets in the AMPK pathway.
Results: PRL stimulation increased the expression of CPT1A (liver isoform) at the mRNA and protein levels in both
breast cancer cell lines, but not in 184B5 cells. In response to PRL, a 20% increase in CPT1 enzyme activity was
observed in MDA-MB-231 cells. PRL treatment resulted in increased phosphorylation of the a catalytic subunit of
AMPK at Thr172, as well as phosphorylation of acetyl-CoA carboxylase (ACC) at Ser79. A siRNA against liver kinase
B1 (LKB1) reversed these effects in breast cancer cells. PRL partially restored CPT1 activity in breast cancer cells in
which CPT1A, LKB1, or AMPKa-1 were knocked down.
Conclusions: PRL enhances fatty acid b-oxidation by stimulating CPT1 expression and/or activity in MCF-7 and
MDA-MB-231 breast cancer cells. These PRL-mediated effects are partially dependent on the LKB1-AMPK pathway,
although the regulation of CPT1 is also likely to be influenced by other mechanisms. Ultimately, increased
CPT1 enzyme activity may contribute to fueling the high energy demands of cancer cells. Targeting metabolic
pathways that are governed by PRL, which has already been implicated in the progression of breast cancer, may
be of therapeutic benefit.
Background
Prolactin (PRL) is released from the anterior pituitary
gland and is known to play an important role during
puberty and during lactation by stimulating the growth
and differentiation of breast tissue [1]. A large body of
literature supports that PRL promotes cell proliferation,
survival, migration/invasion, and angiogenesis (reviewed
in [2]). While a growing number of epidemiological stu-
dies suggest that PRL contributes to the progression of
breast cancer, clinical trials with dopamine agonists
(bromocriptine) targeting pituitary-derived PRL in
serum failed to block cancer progression [3]. However,
it has since been shown that PRL may act as an auto-
crine/paracrine factor in mammary tissue independent
of circulating levels, as it and its receptor (PRLR) are
expressed in normal and cancerous breast epithelium [4],
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appreciable levels in vitro [5,6]. The existence of a func-
tional autocrine/paracrine loop in the breast is further
supported by the finding that breast cancer cell growth
and survival in the presence of PRL blocking antibodies
and antagonists are abrogated [6,7].
PRL plays a reciprocal role in breast epithelial cells
and in adipocytes. During lactation, mammary epithe-
lial cells utilize dietary fat, fatty acids mobilized from
surrounding adipose tissue, and newly synthesized
lipids to produce milk triacylglycerides, a process that
is influenced by both the stage of lactation and the
diet [8]. Assessment of murine gene expression profiles
revealed that during secretory activation at parturition
and during active lactation, genes involved in fatty acid
b-oxidation are largely down-regulated while those
playing a role in lipogenesis are up-regulated, driving
lipid substrates to be utilized for milk fat synthesis [8].
High PRL levels at the onset of lactation and during
breast-feeding influence cellular metabolism by favor-
ing lipogenesis (reviewed in [9]). One mechanism by
which PRL enhances fatty acid biosynthesis in the
milk-producing cells of the bovine mammary gland is
via the transcription factor signal transducer and acti-
vator of transcription 5 (STAT5), which up-regulates
the expression of actyl-CoA carboxylase (ACC), the
rate-limiting enzyme of fatty acid biosynthesis [10]. In
marked contrast to the changes that occur in mam-
mary epithelial cells during lactation, PRL suppresses
lipogenic parameters in cultured human mature adi-
pose tissue [11]. This is evidenced by lower concentra-
tions of malonyl CoA, the product of the first
committed step in lipogenesis, as well as suppressed
expression of the glucose transporter 4 (GLUT4),
w h i c hp l a y sar o l ei ni n s u l i n - d e p e n d e n tg l u c o s eu p t a k e
[11]. PRL also suppresses lipogenesis in murine adipo-
cytes via STAT5A, which directly binds to the fatty
acid synthase (FASN) promoter and represses its tran-
scriptional activation [12].
When a cell experiences high energy demands or is
stressed, the adenosine 5’-monophosphate (AMP)-activated
protein kinase (AMPK), a highly conserved heterotri-
m e r i ce n z y m et h a tg a u g e sc e l l u l a re n e r g ys t o r e s ,i sa c t i -
vated by phosphorylation of its a subunit at Thr172
[13]. AMPK activation leads to either increased glucose
uptake or enhanced fatty acid b-oxidation by mediating
the phosphorylation and inactivation of ACC at Ser79
[14]. ACC inactivation leads to decreased levels of malo-
nyl CoA, resulting in a lift in the allosteric inhibition on
carnitine palmitoyl transferase 1 (CPT1), a transmem-
brane enzyme located in the outer mitochondrial mem-
brane [15]. CPT1 represents the rate-limiting step of
fatty acid b-oxidation [15,16] and catalyzes the transfer of
acyl-CoA from a long-chain acyl-CoA ester to carnitine,
forming acylcarnitine, which is then able to enter the
mitochondria for b-oxidation [17].
While PRL is an important regulator of fatty acid meta-
bolism in normal human breast epithelial cells and adi-
pose tissue and is locally produced in the breast, its role
in mediating b-oxidation via CPT1 in cancer cells has
not been explored. We therefore examined whether PRL
could have differential effects on fatty acid catabolism in
breast cancer cells. Our aims were to investigate its puta-
tive metabolic role by evaluating 1) PRL-mediated
changes in CPT1 expression in breast cancer cells com-
pared to normal breast epithelial cells at the mRNA and
protein levels, 2) changes in CPT1 enzyme activity, and
3) activation of the AMPK pathway via phosphorylation
of its a s u b u n i ta tT h r 1 7 2a n di n a c t i v a t i o no fA C Cv i a
phosphorylation at Ser79. Gaining a better understanding
of how hormones and growth factors differentially affect
breast cancer cells by altering energy production and/or
utilization compared to normal breast epithelial cells may
provide new insights into the development of therapies
for the treatment of breast cancer.
Methods
Cell Culture
All human cell lines were used in accordance with insti-
tutional biosafety guidelines. Cells were obtained from
ATCC, cultured in T-75 flasks (Corning), and passaged
at least twice post-thaw prior to use in experiments.
MCF-7 and MDA-MB-231 were maintained in DMEM,
High Glucose (Invitrogen) supplemented with 10%
fetal bovine serum (FBS) at 37°C in 5% CO2.T h e
184B5 immortalized normal human breast epithelial cell
line was maintained using the MEGM media kit (Clo-
netics) at 37°C in 5% CO2. All cells were passaged no
more than 15 times, after which they were discarded.
Treatment with Recombinant Human PRL
Lyophilized recombinant human PRL (Cedarlane) was
reconstituted in sterile water to 100 μg/ml and stored in
individual aliquots at -20°C to prevent freeze-thawing.
For all experiments other than siRNA transfections, cells
were seeded into 6-well plates at 2.5 × 10
5 cells per well
one day prior to treatment with PRL. The media was
changed and PRL was added at final concentrations of
25, 100, and 500 ng/ml. Cells were treated with PRL for
24 hr and harvested for RNA and protein isolation.
Real Time PCR
Relative mRNA levels were evaluated by real time PCR
using cDNA prepared from 184B5, MCF-7, and MDA-
MB-231 cells. Reactions were based on an input of
500 ng of total RNA and were carried out using Super-
Script III (Invitrogen) following the manufacturer’sp r o -
tocol. Forward (FOR) and reverse (REV) primers used to
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and RPII were designed based on modifications to exist-
ing PCR primer pairs for gene expression detection and
quantification listed in PrimerBank, with annealing tem-
peratures of 60°C (http://pga.mgh.harvard.edu/primer-
bank/index.html). CPT1A:F O R5 ’-CCTCCAGTTGG
CTTATCGTG-3’ and REV 5’-TTCTTCGTCTGGC
TGGACAT-3’,1 3 3b p ;FASN:F O R5 ’-ACAGCGGG
GAATGGGTACT-3’and REV 5’-GACTGGTACAAC
GAGCGGAT-3’,1 8 8b p ;LKB1:F O R5 ’-GAGCTGA
TGTCGGTGGGTATG-3’and REV 5’-CACCTTGCCG
TAAGAGCCT-3’,1 4 4b p ;RPII-1:F O R5 ’-GGGTG
CTGAGTGAGAAGGAC-3’ and REV 5’-AGCCAT
CAAAGGAGATGACG-3’,1 3 8b p ;RPII-2:F O R5 ’-
GAAACGGTGGACGTGCTTAT-3’ and REV 5’-TCTC
CATGCCATACTTGCAC-3’, 157 bp. Cycling conditions
were as follows: 95°C for 1 min, 40 total cycles of 95°C
for 10 sec, 60°C for 25 sec, and melt peak determination
(95°C for 15 sec, increasing from 65°C to 95°C with
0.5°C increments for 5 sec each). Parallel reactions were
carried out for the RPII housekeeping gene to calculate
relative mRNA levels by real time PCR using the 2
-[Δ][Δ]Ct
method [18]. RPII-1 was used for CPT1A and LKB1,a n d
RPII-2 was used for FASN. The amplification efficiencies
were tested for each primer pair, the specificity of the melt
curves was assessed, and the integrity of each product was
verified by gel electrophoresis.
Western Blotting
Total cell lysates were harvested by scraping and sonica-
tion in 1× lysis buffer (20 mM Tris-Cl pH 7.5, 150 mM
N a C l ,1m ME D T A ,1m ME G T A ,1 %T r i t o nX - 1 0 0 ,
+Na2H2P2O7,+ N a 3VO4) supplemented with protease
inhibitors (Roche). Protein concentrations of cleared
lysates were determined using the Bradford assay. A total
of 30 μg of each protein was subjected to SDS-PAGE elec-
trophoresis on 8% polyacrylamide gels. Following transfer
onto PVDF membranes and blocking, blots were incu-
bated in primary anti-CPT1A (1:500 dilution, ProteinTech
Group, Inc), anti-phospho-ACC at Ser79 (1:1000, Cell Sig-
naling Technology), anti-ACC (total; 1:1000, Cell Signaling
Technology), anti-phospho-AMPKa at Thr172 (1:1000,
Cell Signaling Technology), anti-AMPKa1 (total; 1:1000,
Cell Signaling Technology), or anti-LKB1 (1:1000, Cell
Signaling Technology) antibodies followed by incubation
with either anti-mouse or anti-rabbit IgG horseradish
peroxidase (1:3000, Cell Signaling Technology) as
applicable. Signals were detected using the ECL Plus
Western Blotting Detection System (Amersham Bios-
ciences) and exposure to film. Stripped membranes
were reprobed with primary anti-Actin antibody
(1:500, MP) followed by anti-mouse IgG horseradish
peroxidase (1:8000). Densitometric analysis was per-
formed using ImageJ software.
Determination of CPT1 Enzyme Activity
To determine CPT1 enzyme activity, cells were har-
vested after a 24 hr treatment with 100 ng/ml of human
recombinant PRL. Whole cell lysates were prepared as
described for Western blotting. A non-radioactive
method to measure CPT1 activity in cleared lysates was
modified from existing protocols [19-21] and was based
on spectrophotometrically measuring the release of
CoA-SH from palmitoyl CoA at an absorbance of
412 nm using the general thiol reagent 5,5’-dithio-bis-
(2-nitrobenzoic acid) (DTNB). Reaction mixtures con-
taining DTNB and cell lysates were incubated at room
temperature for 30 min to eliminate reactive thiol
groups and the resulting background absorbance was
measured. To start the reaction, palmitoyl-CoA
(100 μM final concentration) prepared in double dis-
tilled water and L-carnitine solution (5 mM final con-
centration in 1 M Tris, pH 8.0) were added to the
reaction mixtures. Immediately after the addition of sub-
strates, kinetic reads at 30 sec intervals were collected
for 90 min by measuring the absorbance at 412 nm.
The difference between absorbance readings with and
without substrates measured the release of CoA-SH, and
values were corrected for total protein. Activity was
defined as nmol CoA-SH released/min/mg protein. The
protein content of the cell lysates was determined using
the Bradford assay.
siRNA Transfections
Cells were seeded at 7 × 10
4 cells per well into 6-well
plates and allowed to adhere by culturing at 37°C, 5%
CO2 for 4 hr. Transient siRNA transfections were car-
ried out using Hiperfect reagent (Qiagen) and siRNAs
specifically targeted against CPT1A, LKB1, and
AMPKa-1 (Qiagen) following the manufacturer’s recom-
mendations, with modifications [22]. The media
was changed 24 hr post-transfection, and 48 hr post-
transfection, the media was changed with the addition
of a final concentration of 100 ng/ml of recombinant
human PRL for 24 hr.
Statistical Analyses
Mean fold changes in mRNA levels were calculated
relative to untreated (-PRL) 184B5 cells. Mean fold
changes for enzyme activity assays following siRNA
transfection were set relative to untreated vehicle. Data
represent the mean ± SEM of three independent
experiments. Data were either analyzed by t-test or
one-way analysis of variance (ANOVA) followed by the
Tukey post-test for multiple comparisons to deter-
mined statistical differences between groups (denoted
by a star or different letters, respectively) using Graph-
Pad Prism analysis software. Results were considered
significant at P < 0.05.
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CPT1A mRNA levels are elevated while FASN mRNA levels
are suppressed in MCF-7 and MDA-MB-231 breast cancer
cells
The expression of two genes, CPT1 and FASN,t h a tp l a y
key roles in fatty acid metabolism (lipolytic versus lypo-
genic) were evaluated at the basal mRNA level in the nor-
mal breast epithelial cell line 184B5 and in MCF-7 and
MDA-MB-231 breast cancer cells. Relative quantification
revealed that CPT1A (the liver isoform) mRNA levels were
significantly elevated in both MCF-7 and MDA-MB-
231 cells compared to 184B5 cells by 5.1 and 7.3 fold,
respectively (Figure 1A; p < 0.0001). Furthermore, FASN
mRNA levels were over 6-fold lower in both breast cancer
cell lines compared to 184B5 cells (Figure 1B; 0.15-fold
compared to 1-fold, respectively, p < 0.0001).
PRL significantly increases CPT1A mRNA and protein
levels in MCF-7 and MDA-MB-231 breast cancer cells
A 24 hr incubation with 100 ng/ml of recombinant
human PRL significantly increased CPT1A mRNA
l e v e l sb y1 . 8 -a n d1 . 6 - f o l di nM C F - 7a n dM D A - M B -
231 breast cancer cells, respectively (Figure 1C; p <
0.0001 and p < 0.001, respectively) compared to
untreated controls. In contrast, CPT1A mRNA levels
did not significantly change in 184B5 cells in response
to treatment with the same dose of PRL (Figure 1C).
Similar results at the mRNA level were obtained when
cells were stimulated with 500 ng/ml of PRL for 24 hr
(results not shown). Stimulation with 100 ng/ml of
PRL also increased CPT1A protein levels in MCF-
7 and MDA-MB-231 cells by approximately 60 and
45% (1 vs. 1.61 ± 0.27-fold, p < 0.05 and 1 vs. 1.45 ±
0.12-fold, p < 0.005, respectively) as determined by
densitometric analysis (Figure 1D). Of note, CPT1A
could only be detected at the protein level in
184B5 after prolonged exposure.
PRL significantly increases CPT1 enzyme activity in MDA-
MB-231 breast cancer cells
To establish whether stimulation with PRL resulted in a
functional effect on fatty acid b-oxidation via CPT1,
whole cell lysates isolated from cells treated for 24 hr
without and with varying doses of recombinant human
PRL (0, 25, 100, and 500 ng/ml) in the presence of the
substrates palmitoyl CoA and carnitine were analyzed
for CPT1 enzyme activity. While not statistically signifi-
cant, culture of 184B5 and MCF-7 cells with a 100 ng/ml
dose of PRL similarly increased CPT1 enzyme activity by
8.3% and 8.5%, respectively (Figure 2A and 2B). In con-
trast, CPT1 enzyme activity was significantly enhanced in
MDA-MB-231 breast cancer cells at both the 100 and
500 ng/ml doses of PRL, resulting in 21.2% and 18.8%
increases, respectively, compared to untreated cells
(Figure 2C; p < 0.02).
Stimulation with PRL induces phosphorylation of the
AMPKa subunit at Thr172 and phosphorylation of ACC at
Ser79
Treatment with 100 ng/ml of recombinant human PRL
resulted in a significant increase in the phosphoryla-
tion of ACC at Ser79 in MCF-7 and MDA-MB-
231 cells (Figure 3A, top panel). Densitometry revealed
that in MCF-7 cells, pACC protein levels increased by
2-fold in response to PRL (1 vs. 2.00 ± 0.22-fold, p <
0.005), with a similar result in MDA-MB-231 cells
(1 vs. 2.43 ± 0.58-fold, p < 0.05). No significant
changes in the phosphorylation status of AMPKa at
Thr172 were observed in 184B5 or MCF-7 cells in
response to stimulation with the same dose of PRL,
while in MDA-MB-231 cells, levels of phosphorylated
AMPKa increased by 2-fold (Figure 3A, middle panel;
1 vs. 2.22 ± 0.38-fold, p < 0.02). Liver kinase
B1 (LKB1) is one of the key upstream kinases that
phosphorylate AMPK at the a subunit [23]. Therefore,
changes in total LKB1 expression in response to PRL
were also examined at the protein and mRNA levels.
The levels of total LKB1 protein were modestly but
significantly increased by 34 and 23% following stimu-
lation with PRL in both MCF-7 and MDA-MB-
231 breast cancer cells, respectively (Figure 3B; 1-fold
vs. 1.34 ± 0.04-fold, p < 0.0001, and 1 vs. 1.23 ± 0.03-
fold, p = 0.0002, respectively). In contrast, no signifi-
cant change was observed in 184B5 cells. Although not
statistically significant, a similar trend was reflected at
the mRNA level (Figure 3B).
Transient knock-down of CPT1A, AMPKa-1, and
LKB1 leads to decreased CPT1 enzyme activity in MCF-
7 and MDA-MB-231 breast cancer cells
In order to investigate the effect of PRL on
CPT1 enzyme activity via activation of the AMPK path-
way, a transient siRNA approach was employed to
knock down CPT1A, AMPKa-1, and its primary
upstream kinase LKB1. The AMPKa-1 subunit was
selected based on our finding that the a-2 subunit was
not expressed at the mRNA level in the three cell lines
(results not shown). The efficiency of the siRNA
approach was assessed at the protein level for CPT1A,
AMPKa-1, and LKB1 (Figure 4A, B, and 4C, respec-
tively). As CPT1A protein was expressed at significantly
lower levels in 184B5 cells compared to MCF-7 or
MDA-MB-231 cells (Figure 4A), the blot verifying
knock-down of CPT1A in this cell line was subjected to
overnight exposure to allow detection of the band at
86 kDa. In all three cell lines, densitometry verified that
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Figure 1 CPT1A mRNA and protein levels are elevated in breast cancer cells and increase in response to PRL. Basal mRNA levels were
determined by real time PCR, revealing that A) CPT1A expression was elevated in both MCF-7 and MDA-MB-231 cells by 5.1 and 7.3 fold,
respectively (p < 0.0001), relative to 184B5 cells, while B) FASN mRNA levels were over 6-fold lower in both breast cancer cell lines relative to
184B5 cells (p < 0.0001). C) A 100 ng/ml dose of PRL significantly increased CPT1A mRNA levels by 1.8- and 1.6-fold in MCF-7 and MDA-MB-231
breast cancer cells, respectively (p < 0.001) relative to untreated cells. In A), B), and C), different letters represent statistical differences between
groups. D) A representative Western blot depicting the 86 kDa CPT1A protein (top). Densitometric analysis (bottom) revealed that 100 ng/ml of
PRL increased protein levels by 61 and 45% in MCF-7 and MDA-MB-231 cells, respectively. All results represent the mean ± SEM of three
independent experiments.
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treated with siRNA compared to vehicle (Figure 4A; p <
0.003). Knock-down of total AMPKa-1 (Figure 4B; p <
0 . 0 3 )a l s oc o r r e s p o n d e dt oas i g n i f i c a n td e c r e a s ei nt h e
level of phosphorylated ACC in all three cell lines (p <
0.003), although no significant changes in CPT1A pro-
tein levels were observed in 184B5, MCF-7, or MDA-
MB-231 cells (Figure 4B). Silencing of LKB1 resulted in
decreased levels of phosphorylated AMPKa in breast
cancer cells (Figure 4C). In MCF-7 cells, LKB1 was
knocked down by 94% (p < 0.0001), also correlating
with a significant decrease in phosphorylated AMPKa
(Figure 4C; p < 0.05). In MDA-MB-231 cells, the down-
stream effects of LKB1 siRNA treatment (84% knock-
down, p < 0.002) were more dramatic, as the levels of
phosphorylated AMPKa were decreased by 90%
(Figure 4C; p < 0.0001). While treatment with this speci-
f i cs i R N Ad i dr e d u c eL K B 1p r o t e i nl e v e l sb y6 4 %i n
184B5 cells (p < 0.001), no change in the phosphoryla-
tion status of AMPKa was observed (Figure 4C).
CPT1 enzyme activity was significantly decreased by 30%
in 184B5 cells treated with CPT1A siRNA compared to
vehicle (Figure 5A; 0.70 ± 0.11-fold relative to vehicle, p <
0.05). No changes in enzyme activity were observed using
siRNAs against either LKB1 or AMPKa-1 (Figure 5A;
0.99 ± 0.04 and 0.99 ± 0.11-fold relative to vehicle, respec-
tively). As shown in Figure 5B, in MCF-7 cells,
CPT1 enzyme activity was decreased by 17, 22, and 25%
following transient transfection with CPT1A, LKB1, and
AMPKa-1 siRNAs, respectively (0.83 ± 0.04, 0.78 ± 0.05,
and 0.75 ± 0.08-fold relative to vehicle, respectively, p <
0.01). Similar decreases were observed in MDA-MB-
231 cells, in which treatment with CPT1A siRNA resulted
in a 24% reduction in enzyme activity (Figure 5C; 0.76 ±
0.07-fold relative to vehicle, p < 0.001) and treatment with
siRNAs targeting LKB1 and AMPKa-1 led to 29 and 23%
reductions, respectively (Figure 5C; 0.70 ± 0.01 and 0.77 ±
0.06-fold relative to vehicle, respectively, p < 0.001).
Decreased CPT1 enzyme activity due to knock-down of
CPT1A, LKB1, and AMPKa-1 is partially attenuated by
treatment with PRL in breast cancer cells
Treatment of cells transiently transfected with CPT1A
siRNA with 100 ng/ml of PRL for 24 hr had no effect on
restoring enzyme activity in 184B5 cells (Figure 6A). In
marked contrast, in both MCF-7 and MDA-MB-231 breast
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Figure 2 PRL significantly increases CPT1 enzyme activity in
MDA-MB-231 breast cancer cells. Enzymatic analysis of cell lysates
harvested 24 hr following culture in the absence and presence of
varying doses of recombinant human PRL (0, 25, 100, and 500 ng/
ml). 100 ng/ml of PRL slightly increased CPT1 enzyme activity in A)
184B5 cells by 8.3% and in B) MCF-7 cells by 8.5%. C) CPT1 enzyme
activity was significantly enhanced in MDA-MB-231 breast cancer
cells treated with 100 and 500 ng/ml of PRL, resulting in 21.2% and
18.8% increases, respectively (p < 0.02). Results are presented as fold
of enzyme activity (nmol CoA-SH released/min/mg protein) relative
to untreated cells and represent the mean ± SEM of three
independent experiments. Different letters represent statistical
differences between groups.
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Figure 4 CPT1A, AMPKa-1, and LKB1 siRNAs effectively knock down expression at the protein level. The efficiency of the transient siRNA
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Page 8 of 15cancer cells in which CPT1A was knocked down, PRL
increased enzyme activity by 10 and 17%, respectively
(Figure 6B and 6C), although levels were not restored to
baseline (reflected by treatment with vehicle only). In each
case, abrogated enzyme activity following treatment with
PRL was restored by 60 and 71%, respectively. A similar,
although not as dramatic, PRL-mediated recovery was
observed in MCF-7 and MDA-MB-231 cells in which
LKB1 was knocked down. Treatment with PRL restored
CPT1 enzyme activity by 8 and 9% (p < 0.05 for MDA-
MB-231 cells), respectively, corresponding with an overall
recovery of 36 and 30% (Figure 6B and 6C). In addition, in
MCF-7 and MDA-MB-231 cells in which AMPKa-1 was
targeted with siRNA, PRL increased enzyme activity by
12 and 9%, respectively (Figure 6B and 6C). This corre-
sponded to an overall recovery toward baseline of 48% and
39%, similar to what was observed for LKB1 in these cells.
Coupled with the enzyme activity data, PRL restored
total LKB1 protein levels in both LKB1 siRNA-transfected
breast cancer cell lines (Figure 7). This effect was more
dramatic in MDA-MB-231 cells, reflected by an overall
2-fold increase (Figure 7, top right panel; from 0.35 ±
0.11-fold to 0.71 ± 0.21-fold relative to vehicle only,
p < 0.05). In addition, PRL-mediated increases in the
level of phosphorylated AMPKa were also more pro-
nounced in MDA-MB-231 cells in which LKB1 was
silenced (Figure 7, middle right panel; from 0.36 ±
0.04-fold to 0.69 ± 0.11-fold relative to vehicle only,
p < 0.007) compared to MCF-7 cells. This rescue was
not evident in 184B5 cells.
Discussion
Changes in the homeostasis of fatty acid metabolism not
only influence the production of cellular energy, but
may also have a dramatic impact on an individual’s
health. Indeed, deregulated lipid metabolism has been
linked to the development of obesity, cardiovascular dis-
ease, insulin resistance and type 2 diabetes, and cancer
[24]. Of clinical relevance, it has recently been shown
that enhanced fatty acid catabolism is linked to che-
moresistance in leukemia [25], and pharmacologically
inhibiting fatty acid b-oxidation sensitizes human leuke-
mia cells to the induction of apoptosis [26]. Despite dec-
ades of research, breast cancer remains one of the most
common cancers world-wide and a leading cause of can-
cer death. In the current study, we have examined breast
A
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Figure 5 CPT1A, LKB1, and AMPKa-1 siRNAs decrease CPT1
enzyme activity in MCF-7 and MDA-MB-231 breast cancer cells.
CPT1 enzyme activity assays were performed on cells transiently
transfected with siRNAs targeting CPT1A, LKB1, or AMPKa-1. A) In
184B5 cells, treatment with CPT1A siRNA decreased enzyme activity by
30% relative to vehicle (p < 0.05). B) CPT1 enzyme activity was
decreased by 17, 22, and 30% relative to vehicle in MCF-7 cells treated
with CPT1A, LKB1, and AMPKa-1 siRNAs, respectively (p < 0.05). C)
In MDA-MB-231 cells, knock-down of CPT1A resulted in a 24%
reduction in enzyme activity relative to vehicle (p < 0.05), and LKB1 and
AMPKa-1 siRNAs led to 29 and 23% reductions relative to vehicle,
respectively (p < 0.05). Different letters represent statistical differences
between groups. Results represent the mean ± SEM of three
independent experiments.
Linher-Melville et al. BMC Cancer 2011, 11:56
http://www.biomedcentral.com/1471-2407/11/56
Page 9 of 15cancer as a metabolic disease, with a focus on lipid
metabolism at the molecular level.
A significant body of research has evaluated the lipo-
genic role of FASN in breast cancer [27-29], and previous
work by Mazzarelli et al. (2007) has reported on the
expression of CPT1, the rate-limiting enzyme governing
long-chain fatty acid catabolism, at the mRNA and pro-
tein levels in MCF-7 cells [30]. In addition, it has been
suggested that in certain cancer cell types, a metabolic
shift may occur in which high rates of glycolysis pro-
mote increased fatty acid oxidation (references in [26]).
It is clear that altered fat metabolism contributes to
cancer. However, a detailed analysis of the expression
and activity of the mitochondrial CPT1 shuttle in breast
cancer cells compared to normal breast epithelial cells
has, to our knowledge, not been performed. While PRL
has been linked with the progression of breast cancer
by promoting cell proliferation, survival, migration/inva-
sion, and angiogenesis (reviewed in [2]), and is known
to differentially affect fatty acid metabolism in breast
epithelial cells and adipocytes, its effect on CPT1 in
breast cancer cells has also not been investigated. We
show here that PRL enhances the expression and/or
activity of CPT1 via activation of the AMPK pathway in
breast cancer cells.
Two CPT1 isoforms, encoded by the liver (CPT1A)
and the muscle/heart (CPT1B) form, are expressed in a
range of tissues and give rise to enzymes with different
kinetic properties [17]. We examined the expression of
CPT1A, which is more widely expressed, and deter-
mined that basal mRNA levels were markedly higher in
both MCF-7 and MDA-MB-231 breast cancer cells
compared to the immortalizedn o r m a lb r e a s te p i t h e l i a l
cell line 184B5. We also investigated the expression of
FASN as a representative lipogenic gene. FASN catalyzes
the synthesis of palmitate from malonyl CoA and acetyl
CoA via NADPH and is minimally expressed in most
normal human tissues, with the exception of cycling
endometrium, the lactating breast, and aggressive sub-
sets of human carcinomas, including certain breast
cancers [31,32]. We found that FASN mRNA levels were
significantly lower in both MCF-7 and MDA-MB-231 cells
compared to 184B5 cells, suggesting that lipolytic pro-
cesses were predominant in these particular breast cancer
cell lines.
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Figure 6 Decreased CPT1 enzyme activity due to knock-down
of CPT1A, LKB1, and AMPKa-1 is partially attenuated by PRL in
breast cancer cells. A) Treatment with 100 ng/ml of PRL for 24 hr
had no effect on CPT1 enzyme activity in 184B5 cells transiently
transfected with CPT1A siRNA. In both B) MCF-7 and C) MDA-MB-
231 breast cancer cells, stimulation of CPT1A siRNA-transfected cells
with PRL increased enzyme activity by 10 and 17%, respectively. A
PRL-mediated recovery of 8 and 9% was also observed in B) MCF-7
and C) MDA-MB-231 cells, respectively, in which LKB1 was knocked
down. In AMPKa1 siRNA-transfected B) MCF-7 and C) MDA-MB-231
cells, PRL increased enzyme activity by 12 and 9%, respectively. The
dotted line corresponds to baseline, representing treatment with
vehicle only. Vehicle = V, CPT1A siRNA = C, LKB1 siRNA = L, and
AMPKa siRNA = A. Results represent the mean ± SEM of three
independent experiments.
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Figure 7 PRL partially restores total LKB1 and phosphorylated AMPKa protein levels in breast cancer cells in which LKB1 is transiently
knocked down. A) Representative Western blots depicting PRL-mediated changes in total LKB1 protein levels and the corresponding changes in
phosphorylated AMPKa (pAMPKa) in 184B5, MCF-7, and MDA-MB-231 cells in which LKB1 was transiently knocked down. B) Densitometry
revealed that PRL induced a 2-fold increase in the level of total LKB1 protein in MDA-MB-231 cells. No changes were observed in 184B5 cells
that underwent a similar treatment. Increased levels of pAMPKa were also observed in MCF-7 and MDA-MB-231 cells (1.4- and 1.9-fold relative to
untreated, respectively) in response to PRL. Different letters represent statistical differences between groups, with ‘ and “ indicate changes within
a cell type. Vehicle = V and LKB1 siRNA = L. Results represent the mean ± SEM of three independent experiments.
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Page 11 of 15Treatment with PRL further increased the expression
of CPT1A at both the mRNA and protein levels in
breast cancer cells, with no changes observed in normal
breast epithelial cells. PRL also enhanced CPT1 enzyme
activity, inducing a more dramatic increase in MDA-
MB-231 cells compared to MCF-7 or 184B5 cells.
Furthermore, PRL partially rescued the knock-down of
CPT1 enzyme activity inducedb ys i R N A - m e d i a t e dt a r -
geting of CPT1A in breast cancer cells, but not in nor-
mal breast epithelial cells. While CPT1 is recognized to
be an important regulatory check-point in controlling
t h er a t eo ff a t t ya c i db-oxidation, increases in
CPT1 protein levels may not be sufficient to enhance
enzyme activity, given the known allosteric inhibition of
CPT1 by malonyl CoA. Relevant to our findings in
breast cancer cells, Bruce et al. (2007) have shown that
fatty acid b-oxidation may nevertheless be activated by
increasing the level of CPT1 protein in both isolated
mitochondria and intact skeletal muscle [33]. These
observations provide evidence that parameters other
than the phosphorylation status of ACC and resulting
changes in malonyl CoA levels may contribute to the
regulation of fatty acid b-oxidation by restoring the
functional content of CPT1 enzyme present in the outer
mitochondrial membrane. One possible explanation for
the finding that PRL increased CPT1 enzyme activity
only in MDA-MB-231 cells and not in MCF-7 cells,
despite increasing CPT1 expression in both cell lines, is
that estradiol may limit CPT1-mediated fatty acid oxida-
tion. This notion is supported by data derived from
s t u d i e si nb o t hr a t sa n dh u m a n s .I th a sb e e ns h o w n
that injecting rats with estradiol lowers hepatic
CPT1 activity, also increasing the sensitivity of CPT1 to
its allosteric inhibitor, malonyl CoA [34]. In women,
fatty acid oxidation is reduced by oral estrogen adminis-
tration [35,36]. Given that MCF-7 cells are estrogen
receptor-positive, this presents an interesting point to
address in future studies. It is possible that although
CPT1 protein levels increase in response to PRL in
MCF-7 cells, the enzyme may be more sensitive to allos-
teric inhibition by malonyl CoA, which could be asso-
ciated with the effects of estrogen.
Activation of the AMPK pathway depends on the cel-
lular AMP:ATP ratio, which changes during states of
high energy expenditure that occur during carcinogen-
esis and in response to stress stimuli [37-40]. The meta-
bolic effects of AMPK are mediated by several distinct
mechanisms, including the phosphorylation/dephosphor-
ylation of down-stream targets [37,38,41]. We have
shown that treatment of breast cancer cells, particularly
MDA-MB-231 cells, with PRL appreciably increases
phosphorylation of the a subunit of AMPK at
Thr172 beyond basal levels, which is linked with the
phosphorylation and inactivation of one of its
downstream effectors, ACC. PRL also imparts a partial
recovery of CPT1 enzyme activity in breast cancer cells
in which AMPKa-1 is transiently knocked down, indi-
cating that PRL-mediated AMPK activation contributes
to the changes in CPT1 enzyme activity reported here.
One potential relationship linking cellular metabolism
and cancer is the interplay between AMPK and LKB1, a
constitutively active serine/threonine kinase (reviewed in
[13,24]). From a mechanistic perspective, the LKB1-
AMPK pathway is activated in response to metabolic
stresses that either inhibit ATP production or accelerate
ATP consumption [42], as is the case in cancer cells.
LKB1 provides constant basal phosphorylation at
Thr172 of the AMPKa subunit, thereby preventing
dephosphorylation in response to changes in the AMP:
ATP ratio [24]. While LKB1 acts as the primary upstream
kinase of AMPKa and serves as a key component of phy-
siological AMPK activation [23], calcium/calmodulin
kinase kinase b (CAMKKb) may also phosphorylate the
AMPKa s u b u n i t[ 4 3 ] ,a n dT G F b-activated kinase
1 (TAK1) has been associated with the AMPK energy
sensing pathway [44]. We found that LKB1 acts as the
primary upstream kinase leading to activation of AMPK
in breast cancer cells, as CAMKKb could not be detected
by Western blot (results not shown) and was therefore
not analyzed further, and knock-down of TAK1 using an
siRNA approach did not affect CPT1 enzyme activity or
the phosphorylation status of AMPKa (results not
shown).
In our model, LKB1 is associated with PRL-mediated
changes in CPT1 activity in breast cancer cells. One
putative means by which PRL increases functional
enzyme activity could be by increasing the expression of
total LKB1. This notion is supported by the finding that
PRL increases total LKB1 protein levels in breast cancer
cells in which LKB1 is transiently knocked down, most
notably in MDA-MB-231 cells. Nevertheless, the partial
rather than full recovery elicited by PRL suggests that,
in addition to changes in fatty acid b-oxidation imparted
by LKB1-AMPKa, CPT1 activity is also likely to be
influenced by other mechanisms. Of note, while
AMPKa and ACC were both phosphorylated in normal
breast epithelial cells treated with PRL, no significant
changes in CPT1 enzyme activity were observed. This
could potentially be related to the sensitivity of these
cells to malonyl CoA, which remains to be investigated.
The action of AMPK on lipid metabolism may also be
mediated at the level of gene transcription via modula-
tion of transcription factors [45]. For example, AMPK
activation suppresses the expression of sterol regulatory
element binding transcription factor 1 (SREBP-1), which
has been shown to regulate the expression of genes
associated with fatty acid and triglyceride biosynthesis,
including FASN [46]. AMPK also phosphorylates p300,
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Page 12 of 15thereby inhibiting its interaction with nuclear receptors
such as peroxisome proliferator-activated receptors
(PPARs) and thyroid hormone, retinoic acid, and reti-
noid X receptors, which in turn may either activate or
repress the expression of diverse target genes that play a
role in lipid metabolism [47]. The partial recovery of
CPT1 enzyme activity in response to PRL in breast
cancer cells suggests that AMPK activation may directly
affect the expression of genes involved in modulating
lipid catabolism, thereby contributing to changes
observed at the level of CPT1 in a manner independent
of ACC inactivation and a lift in the allosteric inhibition
due to changing malonyl CoA levels. Another possibility
is that regulation of these putative genes occurs in an
LKB1-AMPK-independent manner. Interestingly,
PPARa is an important activator of fatty acid catabolism
and may be activated not only by AMPK, but also by
fatty acids, fibrates, and eicosanoids [48]. Tachibana
et al. (2005) have shown that CPT1A is a PPAR-respon-
sive gene, and that induction of PPARa in human hepa-
tocytes increases CPT1A mRNA levels by 2-fold [49].
Our analysis of the human PPARa promoter region led
to the identification of a putative STAT5A/B binding
site [TTC(T/C)N(G/A)GAA, where N represents any
nucleotide; the site identified by computational analysis
in the PPARa promoter is TTCCAAGAA]. As PRL
mediates its effects via, among others, JAK2/
STAT5 signaling in breast cancer cells [50], this could
provide a means by which PRL could directly activate
PPARa transcription independent from LKB1 and
AMPK. It will be of considerable interest to evaluate the
contribution of PPARa on changes in CPT1A expres-
sion and activity in breast cancer cells in response to
PRL in future studies. Importantly, PRL does not restore
CPT1 enzyme activity in normal breast epithelial cells in
which CPT1A, LKB1, or AMPKa-1 are knocked down,
suggesting that distinct pathways are activated in normal
and malignant cells.
Conclusions
In the current study, we have shown that PRL enhances
both the expression and activity of CPT1, the rate-
limiting enzyme of mitochondrial long-chain fatty acid
b-oxidation, in breast cancer cells in vitro.O u rr e s u l t s
reflect what occurs in mature human adipose tissue, and
this altered regulation of lipid metabolism in breast can-
cer cells compared to normal breast epithelial cells in
response to PRL could be a means by which nutrients
such as lipids are utilized to fuel the high energy
demands of cancer cells. Otto Warburg first identified
that metabolism is altered in cancer cells, manifested by
an increase in glucose uptake and preferential ATP pro-
duction via glycolysis [51]. It has since been suggested
that in certain cancers, a high rate of glycolysis, as well
as glutamine metabolism, may actually support the
more efficient oxidation of fatty acids in the mitochon-
dria (references in [26]). Of functional relevance, inhibi-
tion of CPT1-mediated fatty acid oxidation has been
shown to enhance the production of ceramide and to
increase apoptosis [52], and application of a pharmaco-
logic inhibitor of CPT1, etomoxir, results in cytotoxicity
[53]. These findings suggest that inhibition of fatty acid
oxidation may lead to an overall decrease in cancer cell
survival, while an increase in CPT1 activity, such as the
PRL-mediated response reported in the current investi-
gation, may provide a supportive environment for breast
cancer cells.
We propose a mechanism by which PRL elicits its
effect on CPT1A in representative breast cancer cells
(Figure 8). PRL signaling may positively influence
CPT1 enzyme activity by first eliciting an increase in
total LKB1 protein levels, in turn leading to increased
LKB1-mediated activation of the AMPK pathway via
phosphorylation of AMPKa at Thr172 and inactivation
of ACC. Another possible scenario is that PRL, either
directly or indirectly through the activation of AMPK,
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Figure 8 Proposed mechanism by which PRL may affect CPT1
enzyme activity in breast cancer cells. PRL signaling may alter
CPT1 enzyme activity in two distinct manners, with potential cross-
talk. In 1), PRL mediates its effect through LKB1, resulting in
activation of the AMPK pathway via phosphorylation of AMPKa at
Thr172 (pAMPKa) and inactivation of ACC (pACC), culminating in
increased CPT1 enzyme activity. In 2), PRL either directly, or
indirectly through the activation of AMPK, induces PPARa to
increase CPT1A expression, resulting in changes at both the mRNA
and protein levels, thereby increasing CPT1 enzyme activity. Dashed
arrows and ?s indicate components of the pathway(s) that remain
to be conclusively established.
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Page 13 of 15stimulates PPARa to increase CPT1A expression at the
mRNA and protein levels, thereby potentially increasing
CPT1 enzyme activity. To our knowledge, this is the
first study demonstrating that LKB1 plays a role in
activating the AMPK pathway and thereby CPT1 activity
in response to PRL stimulation in breast cancer cells.
Ultimately, targeting metabolic pathways that are gov-
erned by PRL, which has already been implicated in
the progression of breast cancer, may be of therapeutic
benefit.
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